Strategies for viral and non-viral vectors characterization

Vectors Analytics Masterclass 2/6

Appropriate analytical methods are needed to develop next generation vaccines and advanced medical products based on nanodelivery systems, such as recombinant adeno associated viruses (rAAV) and mRNA loaded lipid-based nanoparticles (mRNA-LNPs).

The average diameter and size distribution are some of the most measured attributes during the development of delivery vectors. These data are used for characterization and stability analysis starting from early development stages through process and formulation development all the way to process control, and batch release for clinical trials and marketed products. Particle concentration is a less used attribute, but can be very beneficial during design, formulation and processing of these delivery vectors, as it helps in monitoring yield and informing dosing.

Selection of the most suitable technology to monitor samples will ultimately depend on the specific properties of drug delivery vectors, on their size and polydispersity, as well as what stage of the development process the measurements take place and what is the purpose of the measurement. 

Join us as we take a deep dive into particle sizing techniques and look at several common techniques for determining size distribution and concentration such as:

• dynamic light scattering (DLS)
• nanoparticle tracking analysis (NTA)
• size exclusion chromatography together with static light scattering (SEC-LS)
• multi-angle dynamic light scattering (MADLS)
• asymmetrical field flow fractionation (AF4)  

About this webinar series

This is the second webinar in our “Vector Analytics Masterclass” series. Join us as our team of characterization experts takes you on a deep dive into the methodologies you need for successful vector development. They’ll also show you how to generate robust measurement and help you to understand how adopting a holistic approach to generating data will give you greater confidence in your results. Discover more in our Vector Analytics webinar hub.

Who should attend?

Scientists and project leaders working on the design, process and formulation development of viral and non-viral delivery vectors, such as viral particles, lipid nanoparticles (LNPs) and liposomes for drug and vaccine delivery. 

What will you learn?

• Understand more about the analytical technologies you can use for viral and non-viral delivery vector characterization and understand what the techniques can tell you about your sample
• Learn how to analyze the specific size and concentration characteristics of viral and non-viral vectors with DLS, MADLS, NTA and SEC-SLS measurements. 
• Understand the importance of applying orthogonal techniques Understand the strengths and weaknesses of various characterization techniques for the development of drug delivery vectors